In a double-blind , parallel group , phase 2/3 trial , participants were randomly assigned with permuted blocks in a 1:1 ratio to davunetide ( 30 mg twice daily , intranasally ) or placebo for 52 weeks at 48 centres in Australia , Canada , France , Germany , the UK , and the USA .